Patents by Inventor Jingfang Ju
Jingfang Ju has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365972Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: January 25, 2023Publication date: November 16, 2023Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler
-
Publication number: 20230151363Abstract: The present disclosure provides modified short-interfering ribosomal nucleic acid compositions that have one or more uracil bases replaced a 5-fluorouracil molecule. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within an siRNA nucleotide sequence with a 5-fluorouracil increases the ability of the short interfering RNA to inhibit cancer progression and tumorigenesis when compared to known cancer therapeutics. As such, the present disclosure provides various short-interfering nucleic acid compositions having 5-fluorouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: March 18, 2021Publication date: May 18, 2023Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jingfang JU, Andrew FESLER
-
Patent number: 11584932Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: GrantFiled: October 31, 2018Date of Patent: February 21, 2023Assignee: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler
-
Publication number: 20220226815Abstract: The present disclosure is directed to a microwell array comprising a plurality of wells of micro-size dimensions created on porous materials. The device can be used in various cell and tissue analytical activities, and can be formed using an etching, laminating or imprinting processes.Type: ApplicationFiled: May 8, 2020Publication date: July 21, 2022Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Eric BROUZES, Jin Zhu YU, Anu Priya Bharathi RAJAN, Jingfang JU, Gabor BALAZSI
-
Publication number: 20220145304Abstract: The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and/or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule increases the ability of the microRNA to inhibit cancer progression and tumorigenesis. In addition, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule and replacement of uracil bases with 5-halouracil increases the ability of the microRNA to inhibit cancer development. As such, the present disclosure provides various modified nucleic acid (e.g., microRNA) compositions having gemcitabine molecules incorporated in their nucleic acid sequences and methods for using the same.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang JU, Andrew FESLER
-
Publication number: 20220090076Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: November 24, 2021Publication date: March 24, 2022Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
-
Patent number: 11236337Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: GrantFiled: June 26, 2020Date of Patent: February 1, 2022Assignee: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
-
Publication number: 20200354719Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: June 26, 2020Publication date: November 12, 2020Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler, Younghwa Song, Jun Chung
-
Patent number: 10697020Abstract: The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent.Type: GrantFiled: May 14, 2014Date of Patent: June 30, 2020Assignee: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Mihriban Karaayvaz, Haiyan Zhai
-
Publication number: 20190062754Abstract: The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.Type: ApplicationFiled: October 31, 2018Publication date: February 28, 2019Applicant: The Research Foundation for The State University of New YorkInventors: Jingfang Ju, Andrew Fesler
-
Publication number: 20160090636Abstract: The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent.Type: ApplicationFiled: May 14, 2014Publication date: March 31, 2016Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jingfang JU, Mihriban KARAAYVAZ, Haiyan ZHAI
-
Publication number: 20160024597Abstract: Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate. mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA.Type: ApplicationFiled: October 9, 2015Publication date: January 28, 2016Inventors: Jingfang Ju, Yuan Wang, Bo Song
-
Publication number: 20150152422Abstract: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3? untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.Type: ApplicationFiled: November 26, 2014Publication date: June 4, 2015Inventors: Jingfang Ju, Bo Song, Yuan Wang
-
Patent number: 8927207Abstract: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3? untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.Type: GrantFiled: June 5, 2009Date of Patent: January 6, 2015Assignee: Research Foundation of State University of New YorkInventors: Jingfang Ju, Bo Song, Yuan Wang
-
Patent number: 8343719Abstract: The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid.Type: GrantFiled: October 30, 2007Date of Patent: January 1, 2013Assignee: Research Foundation of State University of New YorkInventors: Jingfang Ju, Yaguang Xi, Nakajima Go
-
Publication number: 20120087992Abstract: Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate, mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA.Type: ApplicationFiled: March 22, 2010Publication date: April 12, 2012Inventors: Jingfang Ju, Yuan Wang, Bo Song
-
Publication number: 20110166201Abstract: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3? untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.Type: ApplicationFiled: June 5, 2009Publication date: July 7, 2011Inventors: Jingfang Ju, Bo Song, Yuan Wang
-
Publication number: 20100203513Abstract: The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid.Type: ApplicationFiled: October 30, 2007Publication date: August 12, 2010Applicant: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Jingfang Ju, Yaguang Xi, Nakajima Go
-
Publication number: 20070178452Abstract: Disclosed is a method in which DNA sequences derived from microsome-associated mRNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification.Type: ApplicationFiled: October 21, 2002Publication date: August 2, 2007Inventors: Pascal Bouffard, John Herrmann, Chunli Huang, Michael Jeffers, Jingfang Ju, Luca Rastelli, Juliette Shimkets, Jan Simons, Bruce Taillon
-
Publication number: 20040038223Abstract: The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: ApplicationFiled: October 1, 2002Publication date: February 26, 2004Inventors: Glennda Smithson, Isabelle Millet, John A. Peyman, Ramesh Kekuda, Jingfang Ju, Li Li, Xiaojia (Sasha) Guo, Meera Patturajan, Kimberly A. Spytek, Shlomit R. Edinger, Karen Ellerman, Uriel M. Malyankar, Tatiana Ort, Linda Gorman, Bryan D. Zerhusen, David W. Anderson, Mei Zhong, Elina Catterton, Weizhen Ji, Charles E. Miller, Luca Rastelli, David J. Stone, Carol E. A. Pena, Suresh G. Shenoy, Richard A. Shimkets, Mark E. Rothenberg, Martin D. Leach, Michele L. Agee, Constance Berghs, Vincent A. DiPippo, Andrew Eisen, Esha A. Gangolli, Daniel K. Rieger, Steven K. Spaderna